JPRN-jRCT2080220364UnknownPhase 2
Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary Osteoporosis
Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.0 sitesStarted: March 20, 2007Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 60age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Osteoporosis patients with fragile bone fracture, low bone mineral density and vertebral fracture
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 3
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary OsteoporosisPrimary OsteoporosisNCT00447915Chugai Pharmaceutical1,265
Unknown
Phase 3
Clinical Study of Ro200-5450po for Primary OsteoporosisPrimary OsteoporosisJPRN-jRCT2080221937Chugai Pharmaceutical Co., Ltd.396
Completed
Phase 2
A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-UMIN000000692CHUGAI PHARMACEUTICAL CO.LTD.260
Unknown
Phase 3
A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-jRCT2080220384Chugai Pharmaceutical Co., Ltd.
Active, not recruiting
Phase 1
Clinical research study to find out if the combination of two study drugs called ribociclib and trametinib is safe and has beneficial effects in people who have solid tumorsSolid tumors, Pancreatic Cancer, Colorectal CancerMedDRA version: 20.0 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033604 Term: Pancreatic cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005019-34-BEovartis Pharma Services AG153